HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR) and maintained a $100 price target.
July 20, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Vir Biotechnology and maintained a $100 price target, potentially indicating positive sentiment towards the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. A reiterated 'Buy' rating and a maintained high price target indicate positive sentiment towards the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100